Clinical effects of amifostine (Ethyol®) in patients treated with carboplatin

European Journal of Cancer

Volumn 32, Issue SUPPL. 4, 1996, Pages

  Budd, G T ^a   Ganapathi, R ^a   Bukowski, R M ^a   Murthy, S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

amifostine; carboplatin; cytoprotection

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; AMIFOSTINE; CARBOPLATIN;

ARTICLE; CANCER; CELL PROTECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA;

AMIFOSTINE; ANIMALS; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CLINICAL TRIALS; HUMANS; MICE; NEOPLASMS; THROMBOCYTOPENIA;

EID: 0029906482     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00317-6     Document Type: Article

References (8)

1. The current status of toxicity protectants in cancer therapy
2. Effect of WR-2721 on the toxicity and antitumour activity of the combination of carboplatin and 5-fluorouracil
3. Effects of the modulating agent WR-2721 on myelotoxicity and antitumour activity in carboplatin-treated mice
4. Phase I study of WR-2721 and carboplatin
5. Phase I trial of carboplatin and amifostine (abstract)
6. Amifostine protects from bone marrow toxicity of combinations of cisplatin and carboplatin without decreasing platinum-DNA adduct formation (abstract)
7. Randomized trial of carboplatin vs. carboplatin + amifostine in advanced malignancy (abstract)
8. Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small cell lung cancer: a randomized phase II study